Cardiff Oncology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-8.4%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.69next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release & Business Update | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Confirmed Objective Response Rate (ORR) in first-line RAS-mutated mCRC (30 mg onvansertib + FOLFIRI/bev) Quarterly72.2%Target: Maintain statistically significant improvement over standard of care (~43.2%) in Phase 3
Cash, Cash Equivalents, and Short-Term Investments Quarterly46.1MTarget: Secure additional capital to fund Phase 3 CRDF-005 registrational trial
Quarterly Net Cash Used in Operating Activities (Cash Burn) Quarterly12.3MTarget: Manage burn rate relative to remaining runway (projected into Q1 2027)
Watch Items
- Nerviano Medical Sciences License Agreement DisputeTrigger: Court ruling or settlement regarding alleged material breach of the onvansertib licenseAction: Monitor legal filings and potential impact on onvansertib development rights
- Initiation and Enrollment of Phase 3 Registrational Trial (CRDF-005)Trigger: First patient dosed in CRDF-005 trialAction: Track clinical trial registry updates and company press releases for enrollment milestones
- Going Concern Status and Capital Raising ActivitiesTrigger: Execution of secondary offering, partnership, or licensing deal to extend runway beyond Q1 2027Action: Review SEC Form 10-Q and 8-K filings for financing terms and going concern disclosures
Research as of 20 Jun 2026